NCT00118183 arm group 08a4df479e15ec87e5cf6d58e58b6e85 [clinicaltrials_resource:NCT00118183/arm-group/08a4df479e15ec87e5cf6d58e58b6e85]
cetuximab [clinicaltrials_resource:0c9359b45d6e7ddb870a9a1f5c424bb6]docetaxel [clinicaltrials_resource:11d7e265e4c66c4bb95a5af83c44eb83]Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer [clinicaltrials:NCT00118183]
arm group [clinicaltrials_vocabulary:arm-group]
NCT00118183 arm group 08a4df479e15ec87e5cf6d58e58b6e85 [clinicaltrials_resource:NCT00118183/arm-group/08a4df479e15ec87e5cf6d58e58b6e85]
Bio2RDF identifier
NCT00118183/arm-group/08a4df479e15ec87e5cf6d58e58b6e85
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... a4df479e15ec87e5cf6d58e58b6e85
description [clinicaltrials_vocabulary:description]
Patients receive docetaxel IV ...... sion or unacceptable toxicity.
identifier
clinicaltrials_resource:NCT00118183/arm-group/08a4df479e15ec87e5cf6d58e58b6e85
title
NCT00118183 arm group 08a4df479e15ec87e5cf6d58e58b6e85
@en
type
label
NCT00118183 arm group 08a4df47 ...... 4df479e15ec87e5cf6d58e58b6e85]
@en